Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The identities of the ubiquitin-ligases active during myogenesis are largely unknown. Here we describe a RING-type E3 ligase complex specified by the adaptor protein,
Ozz
, a novel SOCS protein that is developmentally regulated and expressed exclusively in striated muscle. In mice, the absence of
Ozz
results in overt maturation defects of the sarcomeric apparatus. We identified beta-catenin as one of the target substrates of the
Ozz-E3
in vivo. In the differentiating myofibers,
Ozz-E3
regulates the levels of sarcolemma-associated beta-catenin by mediating its degradation via the
proteasome
. Expression of beta-catenin mutants that reduce the binding of
Ozz
to endogenous beta-catenin leads to Mb-beta-catenin accumulation and myofibrillogenesis defects similar to those observed in
Ozz
null myocytes. These findings reveal a novel mechanism of regulation of Mb-beta-catenin and the role of this pool of the protein in myofibrillogenesis, and implicate the
Ozz-E3
ligase in the process of myofiber differentiation.
...
PMID:Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. 1496 Feb 80